Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Waldenstrom Macroglobulinemia 1Uveal Melanoma 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, B-Cell, Marginal Zone 1Liver Neoplasms 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Intraocular Lymphoma 1Gastrointestinal Stromal Tumors 1Carcinoma, Renal Cell 1Carcinoma, Merkel Cell 1Carcinoma, Hepatocellular 1Burkitt Lymphoma 1

Interventions

pembrolizumab 9avelumab 9Nivolumab 8atezolizumab 4Specimen Handling 4durvalumab 3cemiplimab 3Radiotherapy 3Magnetic Resonance Spectroscopy 3Etoposide 3Cyclophosphamide 3Biopsy 3ALT-803 3talimogene laherparepvec 2fludarabine phosphate 2fludarabine 2domatinostat 2Radiosurgery 2Ipilimumab 2Cisplatin 2Carboplatin 2relatlimab 1oblimersen 1lutetium Lu 177 dotatate 1lenvatinib 1lanreotide 1daromun 1cabozantinib 1antineoplaston AS 2-1 1antineoplaston A10 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Merkel Cell × oblimersen × Clear all
NCT00079131 2013-06-04

Oblimersen in Treating Patients With Merkel Cell Carcinoma

National Cancer Institute (NCI)

Phase 2 Completed
37 enrolled
Dermatologic

Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡